Your Multiomics Hub
Multiomics is changing how molecular medicine is done. Nightingale Health now offers multiple ’omics technologies to accelerate your research, all from a single blood sample and through one simplified workflow.
Your pathway to multiomics
One blood sample. One partner. Multiomics.
Access multiple layers of ’omics data in one place. We now offer metabolomics and proteomics that set the benchmark. Our platform also supports deeper exploration through additional services including genomics and metabolomic risk scores.
Kickstart your research with CoreMetabolomics
Metabolomics is where our story began, and it remains at the core of what we do today.
Our CoreMetabolomics service for blood measures lipoprotein lipids in great detail, fatty acids, amino acids, glycolysis markers, and inflammatory proteins, delivering comprehensive molecular insights reproducibly and cost-effectively.
These biomarkers are associated with diverse aspects of human health, spanning cardiometabolic disease, brain health, and susceptibility to infections. They also reflect the exposome, including smoking, diet, and medications, and provide robust baseline data to support your study.
Now available: Proteomics
CoreMetabolomics by Nightingale Health gives absolute concentrations for key metabolites that sit at the heart of biology — lipids, fatty acids, amino acids, sugars, and ketones. These values compare cleanly across cohorts and time, so trends and effect sizes are easy to read.
Add proteomics to track proteins linked to inflammation, tissue stress, or neurodegeneration, and reveal actors and signals tied to those metabolic changes. The combination lets you connect changes you can quantify in serum chemistry with the proteins that drive or reflect them.
Unlock deeper insights with additional services
Beyond metabolomics and proteomics, we offer additional insights from the same sample material. For a more complete health picture, we offer advanced risk profiling, HbA1c, and Lp(a) risk testing.
Our technology is trusted by researchers worldwide
Replication unlike anywhere else
Nightingale Health’s comprehensive biomarker profiling technology has measured samples from global biobanks and cohort studies. This has created the world’s largest virtual biobank, where scientists worldwide can collaborate and replicate their findings.
Multiomics at the scale of the world’s largest biobanks and cohorts
Nightingale Health multiomics research service provides comprehensive biomarker profiling for cohorts of any size. Because our metabolomics platform has been used to profile all 500,000 participants in the UK Biobank, you can directly combine insights from your study with data on the same biomarkers from the world’s largest health research dataset.
Nightingale Biomarker-Disease Atlas
We are proud to have partnered with these world-leading medical research studies and that our data is available to qualified researchers to amplify and replicate new research findings and increase impact. You can also explore our atlas of biobank associations in UK Biobank.
See our upcoming webinars
Our new research insights
Unlocking half a million metabolomes: UK Biobank data analyzed by Nightingale Health now available to researchers
Dec 05, 2025
New multiomics horizons: Nightingale Health now offers Alamar NULISA CNS and Inflammation proteomics
Nov 11, 2025Meet us at upcoming events
Join us to explore the future of multiomics and connect in person!
EAS Congress
24.5. – 27.5.2026
Athens, Greece
ADA Scientific Sessions
5.6. – 8.6.2026
New Orleans, Louisiana, USA
ESHG Conference
13.6. – 16.6.2026
Gothenburg, Sweden
Customer testimonials
Publications using Nightingale Health technology
Metabolomic profiles predict individual multidisease outcomes
Buergel et al., Nat Med., 2022
The ground-breaking study conducted by researchers from universities in Germany, the Netherlands, and the UK on over 100,000 people demonstrates how one blood test can identify early risk signs for many common diseases. The unique snapshot of a person’s health state captured by Nightingale Health’s proprietary metabolomic blood test was able to improve current health screening tools for several costly diseases, such as heart failure, dementia, and diabetes.
Atlas of plasma NMR biomarkers for health and disease in 118,461 individuals from the UK Biobank
Julkunen et al, Nat Com., 2023
The associations between Nightingale Biomarkers and common chronic diseases like cardiovascular disease or type 2 diabetes have been studied for years. However, in recent studies with data from the UK Biobank, like this oneboth by our internal science team as well as independent study groups, the key findings have been that our biomarkers can predict hundreds of disease endpoints. These findings open countless opportunities to scientists, as they receive not only the wide biomarker panel analyzed from a single blood sample, but also open access to the UK Biobank data which enables them to replicate the study findings in the selection of hundreds of thousands of individuals.
Genome-wide characterization of circulating metabolic biomarkers
Karjalainen et al., Nature, 2024
A genome-wide association study involving 136,000 participants from 33 cohorts (including cohorts like INTERVAL, PROSPER and TUK), identified genetic determinants of 233 circulating metabolic biomarkers analyzed by Nightingale Health. The study found over 8,000 genetic associations across 400 independent loci and identified probable causal genes for two-thirds of these loci through manual curation. The authors emphasize the influence of sample and participant characteristics on the associations, though the inclusion of 33 different cohorts allowed for many robust findings. Comprehensive metabolic profiling was used to explore the impact of known and novel genetic loci on lipoprotein metabolism. Through the public release of their summary statistics, the authors offer new detailed insights into the genetic regulation of metabolism to the whole research community.